GEN1 天
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate
Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...
clinicalpainadvisor.com2 天
In Teenagers With Chronic Pain, Poor Sleep, Depression Affect Later Substance Use
In teenagers with childhood-onset chronic pain unrelated to chronic disease, poor sleep quality and depression were risk factors for substance use in young adulthood.
studyfinds5 天
At-home brain stimulation shows promise as new depression treatment
Researchers explain how a device delivering mild electrical stimulation to the brain can safely and effectively treat depression symptoms.
GlobalData on MSN5 天
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint
Alto Neuroscience (Alto) has reported that its Phase IIb clinical trial of ALTO-100 for treating major depressive disorder ...
BioSpace5 天
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO
Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...
Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint
Alto Neuroscience (ANRO) “announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its ...
Business Wire5 天
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel ...
News Medical6 天
Brain-stimulation therapy at home reduces major depression symptoms
This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in ...